Cor Vasa 2022, 64(Suppl. 4):31-38

The year in cardiovascular medicine 2021: diabetes and metabolic disorders

Francesco Cosentino^1*, Deepak L. Bhatt², Nikolaus Marx³, Subodh Verma^{4, 5, 6, 7}

¹ Cardiology Unit, Department of Medicine Solna, Karolinska Institutet and Karolinska University Hospital, Stockholm SE171 77, Sweden

² Department of Cardiovascular Medicine, Brigham and Women’s Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA

³ Department of Internal Medicine, University Hospital Aachen, RWTH Aachen University, Aachen, Germany

⁴ Department of Pharmacology and Toxicology, University of Toronto, 27 King’s College Circle, Toronto, ON, Canada M5S 3J3

⁵ Division of Cardiovascular Surgery, St Michael’s Hospital, 30 Bond Street, Toronto, ON, Canada M5B 1W8

⁶ Institute of Medical Sciences, University of Toronto, 27 King’s College Circle, Toronto, ON, Canada M5S 3J3

⁷ Department of Surgery, University of Toronto, 27 King’s College Circle, Toronto, ON, Canada M5S 3J3

Received Date: 04 November 2021; Accepted Date: 13 December 2021
Reproduced from: Cosentino F, Bhatt DL, Marx N, Verma S. The year in cardiovascular medicine 2021: diabetes and metabolic disorders. Eur Heart J 2022;43:263–270. https://doi.org/10.1093/eurheartj/ehab876, by permission of Oxford University Press on behalf of the European Society of Cardiology

In the current paper, we review recently published studies that are helping us to understand how the treatment landscape for glucagon-like peptide-1 receptor agonists and sodium glucose cotransporter 2 inhibitors is moving forward. We have also included relevant articles related to cardiovascular disease prevention in the setting of obesity, atherogenic dyslipidaemia and chronic kidney disease.

Klíčová slova: Diabetes mellitus; Obesity; Heart failure; GLP-1 receptor agonists; SGLT2 inhibitors; Aldosterone receptor antagonism; Omega-3 fatty acid mixtures

Vloženo: 20. prosinec 2022; Přijato: 20. prosinec 2022; Zveřejněno: 30. prosinec 2022  Zobrazit citaci